Stocks Health care OCS
NASDAQ · Health careOculis Holding AG (OCS)
It posted a net loss of CHF 99M. In fiscal 2025 capital spending exceeded operating cash flow by CHF 66.6M. At December 31, 2025 it held CHF 81.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 4, 2026.
Key facts about Oculis Holding AG
- Net worth
- Oculis Holding AG has a market value (market cap) of $440.1M at the latest share price, and shareholders' equity of CHF 196.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used CHF 66.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 4, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Oculis Holding AG does
Oculis Holding AG is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OCS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -CHF 99M | -CHF 1.89 | -CHF 66.6M |
| 2024 | n/a | -CHF 85.8M | -CHF 2.12 | -CHF 49.1M |
| 2023 | n/a | -CHF 88.8M | -CHF 2.97 | -CHF 55.1M |
| 2022 | n/a | -CHF 38.7M | -CHF 11.32 | -CHF 25.1M |
| 2022 | n/a | -CHF 18.6M | -CHF 5.84 | -CHF 13.9M |
| 2020 | n/a | -CHF 14.9M | -CHF 5.04 | -CHF 12M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Oculis Holding AG has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- September 30, 2026
- August 10, 2026
- August 6, 2026
- August 6, 2026
- June 25, 2026
- June 1, 2026
- May 14, 2026
- May 11, 2026
- April 29, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Oculis Holding AG did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns OCS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| LSP 7 Cooperatieve U.A.13G, passive with 1 related filers | 11.8% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 59 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| EQT Fund Management S.a r.l. | 6,950,294 | +1,050,000 |
| Aberdeen Group plc | 2,159,809 | +412,863 |
| Millennium Management LLC | 2,042,467 | +1,129,433 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,506,250 | -174,033 |
| Citadel Advisors LLC | 987,204 | +825,920 |
| Braidwell LP | 834,183 | new |
| Perceptive Advisors LLC | 808,827 | +315,000 |
| Saturn V Capital Management LP | 684,880 | +168,119 |
| SR One Capital Management, LP | 641,022 | 0 |
| Siren, L.L.C. | 625,000 | new |
| Ameriprise Financial Inc | 619,922 | new |
| Wellington Management Group Llp | 540,056 | -805,672 |
| PFM Health Sciences, LP | 436,042 | new |
| Franklin Resources Inc | 434,751 | new |
| Manufacturers Life Insurance Company, The | 398,980 | new |
| Marshall Wace, Llp | 394,880 | new |
| Nan Fung Group Holdings Ltd | 300,565 | -50,180 |
| Qube Research & Technologies Ltd | 262,113 | +241,623 |
| Morgan Stanley | 225,083 | +158,846 |
| Point72 Asset Management, L.P. | 220,403 | +164,276 |
Insiders
Questions about OCS
What does Oculis Holding AG do?
Oculis Holding AG is a company in the Health care sector, listed on NASDAQ as OCS. Its shares trade on NASDAQ under the ticker OCS.
What is Oculis Holding AG's net worth?
Oculis Holding AG has a market value (market cap) of $440.1M at the latest share price, and shareholders' equity of CHF 196.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Oculis Holding AG profitable?
No. In fiscal 2025 it reported a net loss of CHF 99M.
When did Oculis Holding AG last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 4, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 3, 2026.
Similar companies
Compare OCS with
Follow OCS
Get an email when Oculis Holding AG files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Oculis Holding AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.